MA54948A - Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète - Google Patents

Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète

Info

Publication number
MA54948A
MA54948A MA054948A MA54948A MA54948A MA 54948 A MA54948 A MA 54948A MA 054948 A MA054948 A MA 054948A MA 54948 A MA54948 A MA 54948A MA 54948 A MA54948 A MA 54948A
Authority
MA
Morocco
Prior art keywords
derivatives
pkm2
thieno
pyrrole
obesity
Prior art date
Application number
MA054948A
Other languages
English (en)
Inventor
Jingjing Ji
Tao Liu
Zhihua Sui
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MA54948A publication Critical patent/MA54948A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054948A 2019-02-13 2020-02-12 Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète MA54948A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962805040P 2019-02-13 2019-02-13

Publications (1)

Publication Number Publication Date
MA54948A true MA54948A (fr) 2021-12-22

Family

ID=69941460

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054948A MA54948A (fr) 2019-02-13 2020-02-12 Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète

Country Status (14)

Country Link
US (1) US20220127267A1 (fr)
EP (1) EP3924056A1 (fr)
JP (1) JP2022520090A (fr)
KR (1) KR20210128435A (fr)
CN (1) CN113646050A (fr)
AU (1) AU2020221837A1 (fr)
BR (1) BR112021015996A2 (fr)
CA (1) CA3129829A1 (fr)
CO (1) CO2021011919A2 (fr)
IL (1) IL285445A (fr)
MA (1) MA54948A (fr)
MX (1) MX2021009743A (fr)
SG (1) SG11202108744WA (fr)
WO (1) WO2020167976A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364240B2 (en) 2017-08-15 2022-06-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
CA3183980A1 (fr) * 2020-07-21 2022-01-27 The Regents Of The University Of Michigan Compositions et procedes d'activation de la pyruvate kinase
WO2022170200A1 (fr) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. Dérivés de 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5-yl]-éthanone servant d'activateurs de pyruvate kinase (pkr) et de pkm2 pour le traitement de la drépanocytose
CA3231728A1 (fr) 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Nouveaux composes
WO2023079294A1 (fr) 2021-11-05 2023-05-11 Sitryx Therapeutics Limited Dérivés de phtalazine utilisés comme modulateurs de la pyruvate kinase
CN118434720A (zh) 2021-12-22 2024-08-02 西特瑞治疗有限公司 作为丙酮酸激酶调节剂的酞嗪衍生物
MX2024007744A (es) 2021-12-22 2024-07-01 Sitryx Therapeutics Ltd Derivados de ftalazina como moduladores de piruvato quinasa.
CN115487190A (zh) * 2022-11-01 2022-12-20 复旦大学附属中山医院 丙酮酸激酶m2激活剂在制备治疗系统性红斑狼疮的药物中的应用
CN116808223A (zh) * 2023-08-04 2023-09-29 复旦大学附属中山医院 丙酮酸激酶m2激活剂在制备治疗银屑病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173415B1 (fr) * 2008-10-09 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Activateurs de la pyruvate kinase humaine
US8785450B2 (en) 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP2704719B1 (fr) * 2011-05-03 2018-02-21 Agios Pharmaceuticals, Inc. Activateurs de pyruvate kinase destinés à être utilisés pour allonger la durée de vie des érythrocytes et traiter l'anémie
CA2834692A1 (fr) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Activateurs de la pyruvate kinase destines a une utilisation therapeutique
PL3406251T3 (pl) 2011-05-03 2024-04-29 Agios Pharmaceuticals, Inc. Aktywatory kinazy pirogronianowej do stosowania w terapii
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US11364240B2 (en) * 2017-08-15 2022-06-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders

Also Published As

Publication number Publication date
MX2021009743A (es) 2021-11-12
BR112021015996A2 (pt) 2021-11-09
EP3924056A1 (fr) 2021-12-22
CO2021011919A2 (es) 2021-12-10
KR20210128435A (ko) 2021-10-26
CA3129829A1 (fr) 2020-08-20
SG11202108744WA (en) 2021-09-29
JP2022520090A (ja) 2022-03-28
WO2020167976A1 (fr) 2020-08-20
CN113646050A (zh) 2021-11-12
AU2020221837A1 (en) 2021-09-02
US20220127267A1 (en) 2022-04-28
IL285445A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MA54948A (fr) Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète
MA51520A (fr) Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer
WO2008063202A3 (fr) Composés hétérobicycliques de thiophène et leurs méthodes d'utilisation
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
MA51568A (fr) Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
WO2006015060A3 (fr) Composes isoindoline et methodes d'utilisation de ces derniers
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
EP3037421A3 (fr) Inhibiteurs de mlk et procédés d'utilisation
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2009117277A3 (fr) Combinaisons de conjugués anticorps anti-her2-médicament et d’agents chimiothérapiques, et procédés d’utilisation
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
MX2020009668A (es) Métodos novedosos.
MA32506B1 (fr) Nouveaux composes
EA201390712A1 (ru) Производные пиридазина, композиции и способы лечения когнитивного нарушения
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
IL255782A (en) Pharmacotherapeutic agents of levatiracetam with prolonged release
MA31798B1 (fr) Composés organiques
MA55594A (fr) Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune
EA202190431A1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
WO2014194242A3 (fr) Inhibiteurs de flt3 et leurs utilisations
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).